Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -12.97
- Piotroski Score 3.00
- Grade Equal-Weight
- Symbol (BLUE)
- Company bluebird bio, Inc.
- Price $0.52
- Changes Percentage (3.07%)
- Change $0.02
- Day Low $0.51
- Day High $0.54
- Year High $5.53
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $12.50
- High Stock Price Target $25.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.63
- Trailing P/E Ratio -1.44
- Forward P/E Ratio -1.44
- P/E Growth -1.44
- Net Income $-211,913,000
Income Statement
Quarterly
Annual
Latest News of BLUE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Columbus Blue Jackets 2024-25 season preview: Playoff chances, projected points, roster rankings
Blue Jackets President Waddell mourns Gaudreau's passing, highlighting the team's emotional and on-ice challenges. The focus shifts to prospects like Fantilli and Jiřiček, potential stars in the mak...
By The New York Times | 19 hours ago -
Blue Jays takeaways: Vlad Guerrero Jr. falls short of 200 hits and offseason priorities
Toronto Blue Jays' Vladimir Guerrero Jr. fell short of 200 hits in a historic season. Despite missing the milestone, Guerrero had an outstanding year with impressive stats. Bowden Francis emerged as a...
By The New York Times | 1 day ago -
Jonah Bride has 2 RBIs, Marlins sweep Blue Jays with 3-1 win
Miami Marlins defeated the Toronto Blue Jays 3-1, sweeping the series. Ryan Weathers excelled, and Anthony Bender earned his first save. The Blue Jays struggled, finishing with a 74-88 record. Both te...
By CBS News | 1 day ago